So, it may be necessary to consider the inflammatory markers, such as CRP and PDW, when exploring for the possible treatments in PCa patients [9, 29–32] and eliminating or inhibiting chronic inflammation may be one of the supplementary methods for the treatment of PCa combined with MetS. Here, CRP is linked to posterior cortical atrophy.